Synthego
Synthego is a genome engineering company that develops synthetic guide RNA, automated CRISPR platforms, and engineered cell production for research and therapeutic development. The company builds machine learning-driven tools and GMP manufacturing capabilities for CRISPR-based medicines and life sciences research.
Acquired
Synthego has been acquired
This company is no longer available on our private secondary market.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2012
Employees
156–259
Total Funding
$651M
4 rounds
Latest Valuation
$1.2B
September 2021
Funding
Total raised $651M across 4 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series E
Date
September 2021
Amount
$200M
Valuation
—
Lead Investors
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| September 2021 | Series E | $200M | — | Perceptive Advisors, RA Capital Management |
| January 2020 | Series C | $100M | — | Founders Fund |
| August 2018 | Series B | $110M | — | Founders Fund |
Prominent Investors
Leadership
Craig Christianson
Chief Executive Officer
Paul Dabrowski
Co-Founder, Board Director
Michael Dabrowski
Co-Founder
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Editas Medicine
CRISPR/Cas9 gene editing platform for therapeutic development
CRISPR Therapeutics
CRISPR-Cas9 gene editing technology for disease treatment
Beam Therapeutics
Base editing and prime editing platforms for gene correction
Intellia Therapeutics
CRISPR-based in vivo genome editing therapeutics
Sangamo Therapeutics
Zinc finger protein and gene therapy platform
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.